Drug Profile
Romyelocel-L - Cellerant Therapeutics
Alternative Names: CLT-008; hMPC - Cellerant Therapeutics; Human myeloid progenitor cells - Cellerant TherapeuticsLatest Information Update: 27 Sep 2022
Price :
$50
*
At a glance
- Originator Cellerant Therapeutics
- Class Cell therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Transplant rejection
- No development reported Neutropenia
Most Recent Events
- 27 Sep 2022 No development reported - Phase-III for Neutropenia in USA (IV)
- 21 Apr 2020 Phase-III clinical trials in Neutropenia in USA (IV) (Cellerant Therapeutics pipeline, April 2020)
- 21 Apr 2020 Preclinical trials in Transplant rejection (Prevention) in USA (IV) (Cellerant Therapeutics pipeline, April 2020)